Please enable JavaScript.

Coggle requires JavaScript to display documents.

CMV - IL28B (Corrales et al. 2016 (Intro (Type III (l) interferons (IFNs),…

- - - - i) absence of documented CMV DNAemia prior tothe time of immunological analysis; (ii) availability ofCMV-speciﬁc CD8þT-cell immunity data; (iii) avail-ability of at least three plasma specimens for IL-28Bquantitation obtained after Allo-SCT and prior to thetime of immunological analyses; and (iv) availabilityof data on the donor IL28B genotype.
      - Patients with a preced-ing episode of CMV DNAemia were excluded deliber-ately, as CMV replication triggers CMV-speciﬁc T-cel
  - - - Thirty-six of thesepatients harbored the donor IL28BC/C genotype, 39the C/T genotype and 10 were homozygous for theminor T allele
      - a trend towards a lowerincidence of CMV DNAemia was observed forpatients carrying the T/T genotype (10% vs. 26% forC/T and C/C patients; P ¼ 0.262)
      - Detectable CMV-speciﬁc IFN-g CD8þT-cell responses were observed more frequently in T/T patients (90%) than in theirC/T and C/C counterparts (77%), although the differ-ence did not re ach statistical signiﬁcance (P ¼ 0.525).
    - - atients harboring thedonor IL28B T/T genotype displayed CMV-speciﬁcIFN-g CD8þT-cell responses of higher magnitude(median, 1.79 cells/ ml) than their C/T and C/C coun-terparts (median, 0.45 and 0.19 cells/ml, respectively)
      - plasmaCMV DNA peak level during episodes of active CMVinfection was substantially lower in patients harbor-ing the IL28B T/T genotype than in the latter group,
      - fewer patients inthe T/T group received pre-emptive antiviral therapy(33% in the T/T group, 65.2% in the C/T group, and80% in the C/C group; P ¼ 0.05).